A rap video used to motivate Insys Therapeutics’ salesforce into promoting higher doses of its opioid drug Subsys is the latest piece of evidence in the increasingly-bizarre trial of chairman Jo
Sanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company has forecast growth for 2019 thanks to higher than expected quarterly earnings and
OPEN Health has restructured its eight businesses into four specialist practices, in a move that will see it retire names such as LEC, Reynolds-MacKenzie and Harvey Walsh.